Summary
Special conditions - tricine buffer containing Ca2+ and Mg2+, 22°C (TCM) — allow to label a much higher proportion of muscarinic receptors by [3H]cis-methyldioxolane (CD) than hitherto described (Vickroy et al. 1984 a). Taking the maximum number of binding sites, B max, of [3H]QNB as 100%, B max of [3H]CD amounts to 83% in the rat heart instead of the reported 17%, 33% in the cerebral cortex instead of 6%, 20% in hippocampus and 55% in pons/medulla. In the salivary glands specific binding was negligible. The affinities of a number of muscarinic agonists and antagonists to [3H]CD and [3H]QNB binding sites in different tissues of the rat are compared. Apparent affinities of agonists are much higher in the [3H]CD system, affinities of antagonists are slightly higher in the [3H]QNB system. In both assay systems receptors of heart and pons/ medulla membranes seem to have similar drug specificity. They differ somewhat from those in the cortex. Receptors in the salivary glands, however, seem to be completely different from those in the other three tissues. In the heart [3H]CD binding can be abolished almost completely by GppNHp. In the cortex about half of the [3H]CD binding is susceptible to GppNHp. The reduction of binding in the cortex is due to a change in B max and not in the dissociation constant K D. Competition of unlabelled pirenzepine with [3H]CD: In heart and pons/medulla only low affinity sites for pirenzepine (M2-receptors) are labelled by [3H]CD. In regions rich in M1 receptors like hippocampus (80% M1 receptors) or cortex (65–70% M1 receptors) the proportion of M1 receptors labelled by [3H]CD is smaller than expected considering the concentration of M1 receptors present in these tissues. Thus [3H]CD, under the conditions described in this paper, seems to label preferentially but not exclusively M2 receptors in their agonist high affinity form.
Similar content being viewed by others
References
Bevan P (1984) [3H]Oxotremorine-M binding to membranes prepared from rat brain and heart: Evidence for subtypes of muscarinic receptors. Eur J Pharmacol 101:101–110
Birdsall NJM, Burgen ASV, Hulme EC (1978) The binding of agonists to brain muscarinic receptors. Mol Pharmacol 14: 723–736
Birdsall NJM, Hulme EC, Stockton JM (1984) Muscarinic receptor heterogeneity. Trends in Pharmacol Sci Suppl: 4–8
Bittiger H, Heid J (1981) Radioreceptor assay for muscarinic agonists using [3H]cis-methyldioxolane. Experientia 37:638
Bürgisser E, De Lean A, Lefkowitz RJ (1982) Reciprocal modulation of agonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc Natl Acad Sci USA 79:1732–1736
Closse A, Gmelin G (1985) Comparison of the affinities of muscarinic agonists and antagonists in heart and cortex tissues with the response at the sympathetic ganglia and at the ileum. (26. Frühjahrstagung der Deutschen Pharmakologischen Gesellschaft 12–15.3.1985 in Mainz). Naunyn-Schmiedeberg's Arch Pharmacol 329: Suppl R73
Cortés R, Palacios JM (1986) Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies. Brain Res 326:227–238
Ehlert FJ, Dumont Y, Roeske WR, Yamamura HI (1980a) Muscarinic receptor binding in rat brain using the agonist [3H]cis-methyldioxolane. Life Sci 26:961–967
Ehlert FJ, Yamamura HI, Triggle DJ, Roeske WR (1980b) The influence of guanyl-5′-yl-imidodiphosphate and sodium chloride on the binding of the muscarinic agonist [3H]cismethyldioxolane. Eur J Pharmacol 61:317–318
Ehlert FJ, Roeske WR, Yamamura HI (1983) The nature of muscarinic receptor binding. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Plenum Press, New York 17:241–283
Gurwitz D, Kloog Y, Sokolovsky M (1984) Recognition of the muscarinic receptor by its endogenous neurotransmitter: Binding of [3H]acetylcholine and its modulation by transition metal ions and guanine nucleotides. Proc Natl Acad Sci USA 81:3650–3654
Gurwitz D, Kloog Y, Sokolovsky M (1985) High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides. Mol Pharmacol 28:297–305
Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980) Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90–93
Harden RT, Scheer AG, Smith MM (1982) Differential modification of the interaction of cardiac muscarinic cholinergic and beta-adrenergic receptors with a guanine nucleotide binding component(s). Mol Pharmacol 21:570–580
Hedlund B, Bartfai T (1981) Binding of [3H]pilocarpine to membranes from rat cerebral cortex. Naunyn-Schmiedeberg's Arch Pharmacol 317:126–130
Hulme EC, Birdsall NJM, Burgen ASV, Mehta P (1978) The binding of antagonists to brain muscarinic receptors. Mol Pharmacol 14:737–750
Hulme EC, Berrie CP, Birdsall NJM, Jameson M, Stockton JM (1983) Regulation of muscarinic agonist binding by cations and guanine nucleotides. Eur J Pharmacol 94:59–72
Korn SJ, Martin MW, Harden TK (1983) N-Ethylmaleimide-induced alteration in the interaction of agonists with muscarinic cholinergic receptors of rat brain. J Pharmacol Exp Ther 224:118–126
Nukada T, Haga T, Ichiyama A (1983) Muscarinic receptors in porcine caudate nucleus I. Enhancement by nickel and other cations of [3H]cismethyldioxolane binding to guanyl nucleotide-sensitive sites. Mol Pharmacol 24:366–373
Potter LT, Flynn DD, Hanchett HE, Kalimoski DL, Luber-Narod J, Mash DC (1984) Independent M1 and M2 receptors: ligands, autoradiography and functions. Trends in Pharmacol Sci Suppl:22–31
Sokolovsky M (1984) Muscarinic receptors in the central nervous system. Internat Rev of Neurobiol 25:139–181
Tobler HJ, Engel G (1983) Affinity spectra: a novel way for the evaluation of equilibrium binding experiments. Naunyn-Schmiedeberg's Arch Pharmacol 322:183–192
Vickroy TW, Roeske WR, Yamamura HI (1984a) Pharmacological differences between the high affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cis-methyldioxolane. J Pharmacol Exp Ther 229:747–755
Vickroy TW, Watson M, Yamamura HI, Roeske WR (1984b) Agonist binding to multiple muscarinic receptors. Fed Proc 43: 2785–2790
Waelbroeck M, Robberecht P, Chatelain P, Christophe J (1982) Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites. Mol Pharmacol 21:581–588
Wastek GJ, Yamamura HI (1978) Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease. Mol Pharmacol 14:768–780
Watson M, Yamamura HI, Roeske WR (1983) A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provides evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci 32:3001–3011
Wells JW (1983) Mechanistic interpretation of radioligand binding patterns of neurohumoral receptors. J Neurochem Suppl 41: S162
Wreggett KA, De Lean A (1984) The ternary complex model. Its properties and application to ligand interactions with D2-dopamine receptor of the pituitary gland. Mol Pharmacol 26:214–227
Author information
Authors and Affiliations
Additional information
Send offprint requests to A. Closse at the above address
Rights and permissions
About this article
Cite this article
Closse, A., Bittiger, H., Langenegger, D. et al. Binding studies with [3H]cis-methyldioxolane in different tissues. Naunyn-Schmiedeberg's Arch Pharmacol 335, 372–377 (1987). https://doi.org/10.1007/BF00165550
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00165550